Leukotriene Receptor

Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.

Leukotriene Receptor Inhibitors, Agonists & Antagonists

(Rac)-HAMI 3379

Cat. No.: HY-112248

(Rac)-HAMI 3379 is the racemate of HAMI 3379. HAMI 3379 is a potent and selective **Cysteinyl leukotriene ($CysLT_2$) receptor** antagonist.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

(S)-Verapamil D7 hydrochloride

((S)-(-)-Verapamil D7 hydrochloride) Cat. No.: HY-135336AS

(S)-Verapamil D7 hydrochloride ((S)-(-)-Verapamil D7 hydrochloride) is a deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

(S)-Verapamil hydrochloride

((S)-(-)-Verapamil hydrochloride) Cat. No.: HY-135336A

(S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits **leukotriene C4 (LTC4)** and **calcein** transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells.



Purity: 99.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(S)-Verapamil-d6 hydrochloride

((S)-(-)-Verapamil-d6 hydrochloride) Cat. No.: HY-135336AS1

(S)-Verapamil-d6 ((S)-(-)-Verapamil-d6) hydrochloride is the deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits **leukotriene C4 (LTC4)** and **calcein** transport by MRP1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

11-Keto-beta-boswellic acid

(11-Keto-β-boswellic acid) Cat. No.: HY-N2056

11-Keto-beta-boswellic acid (11-Keto-β-boswellic acid) is a pentacyclic triterpenic acid of the oleogum resin from the bark of the Boswellia serrate tree, popularly known as Indian Frankincense.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

12S-HHT

(12(S)-HHTrE) Cat. No.: HY-113330

12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H_2 (PGH_2) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for **BLT2** that fully activates **BLT2** in vivo.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-O-Demethylnobiletin

(5-Demethylnobiletin) Cat. No.: HY-N1942

5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Sideritis tragoriganum, is a direct inhibition of 5-LOX (IC_{50}=0.1 μM), without affecting the expression of COX-2.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Ablukast

(Ro 23-3544) Cat. No.: HY-118958

Ablukast (Ro 23-3544) is a specific and active **leukotriene receptor** antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction. Ablukast is **LTD4 receptor** antagonist.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Amelubant

(BIIL 284) Cat. No.: HY-19304

Amelubant (BIIL 284) is a potent, oral and long acting **LTB_4 receptor** antagonist, negligibly binds to LTB_4 receptor, with K_is of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a prodrug of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS-35

Cat. No.: HY-101946

AS-35 is an orally effective, potent and selective antagonist of **leukotrienes**, antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with IC_{50} values of 8 nM, 4 nM and 3 nM, respectively, and has antiallergic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

BAY-u 9773

Cat. No.: HY-107609

BAY-u 9773 is a non-selective antagonist of the **CysLT receptors** (cysteinyl leukotrienes receptors) with about the same IC_{50} for CysLT[1] and CysLT[2]. BAY-u9773 is used for the inhibition of LT responses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIIL-260 hydrochloride

Cat. No.: HY-114641A

BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor **LTB_4** antagonist, with anti-inflammatory activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Bunaprolast

(U66858)

Cat. No.: HY-U00170

Bunaprolast (U66858) is a potent inhibitor of **LTB_4** production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of **lipoxygenase** and **TXB_2** release.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAY10583

Cat. No.: HY-122124

CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CI-949

Cat. No.: HY-U00364

CI-949 is an allergic mediator release inhibitor, which inhibits **histamine**, **leukotriene C_4/D_4 (LTC_4/LTD_4)**, and **thromboxane B_2 (TXB_2)** release with **IC_{50}**s of 11.4 μM, 0.5 μM and 0.1 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-105696

(Pfizer 105696)

Cat. No.: HY-19193

CP-105696 is a potent and selective **Leukotriene B_4** Receptor antagonist, with an **IC_{50}** of 8.42 nM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 5 mg

CP-96021 hydrochloride

Cat. No.: HY-101731

CP-96021 hydrochloride is a balanced, combined, potent and orally active **leukotriene D4 (LTD4)/platelet activating factor (PAF)** receptor antagonist with **K_i** values of 34 nM and 37 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-96486

Cat. No.: HY-100316

CP-96486 is a potent and orally active leukotriene D_4 (**LTD_4**)/platelet activating factor (**PAF**) receptor antagonist with **K_i**s of 20 and 24 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Darbufelone

(CI-1004)

Cat. No.: HY-101438

Darbufelone is a dual inhibitor of cellular **$PGF_{2\alpha}$** and **LTB_4** production. Darbufelone potently inhibits **PGHS-2** (**IC_{50}**= 0.19 μM) but is much less potent with **PGHS-1** (**IC_{50}**=20 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

Darbufelone mesylate

(CI-1004 mesylate)

Cat. No.: HY-101438A

Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular **$PGF_{2\alpha}$** and **LTB_4** production. Darbufelone potently inhibits **PGHS-2** (**IC_{50}** = 0.19 μM) but is much less potent with **PGHS-1** (**IC_{50}**= 20 μM).



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DW-1350

Cat. No.: HY-100173

DW-1350 is a **LTB_4 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Etalocib

(LY293111; VML 295)

Cat. No.: HY-13628

Etalocib (LY293111), an orally active **leukotriene B_4 receptor** antagonist, inhibits the binding of **[^{3}H]LTB_4**, with a **K_i** of 25 nM. Etalocib (LY293111) prevents LTB_4-induced calcium mobilization with an **IC_{50}** of 20 nM. Etalocib (LY293111) induces apoptosis.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fiboflapon

(GSK2190915; AM-803)

Cat. No.: HY-15874

Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (**FLAP**) inhibitor with a potency of 2.9 nM in FLAP binding, an **IC_{50}** of 76 nM for inhibition of **LTB4** in human blood.



Purity: 98.54%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Fiboflapon sodium

(GSK2190915 sodium salt; AM-803 sodium)

Cat. No.: HY-15874A

Fiboflapon sodium (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (**FLAP**) inhibitor with a potency of 2.9 nM in FLAP binding, an **IC_{50}** of 76 nM for inhibition of **LTB4** in human blood.



Purity: 99.91%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gemilukast

(ONO-6950)

Cat. No.: HY-16780

Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors **($CysLT_1$ and $CysLT_2$)** antagonist, with **IC_{50}s** of 1.7, 25 nM for human $CysLT_1$ and $CysLT_2$, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GPBAR1-IN-3

Cat. No.: HY-145234

GPBAR1-IN-3 (Compound 14) is a selective **GPBAR1** agonist (**EC_{50}**=0.17 μM) and a $CysLT_1R$ antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HAMI 3379

Cat. No.: HY-112248A

HAMI 3379 is a potent and selective **$CysLT_2$** receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KP496

Cat. No.: HY-U00253

KP496 is a selective, dual antagonist for **Leukotriene D4 receptor** and **Thromboxane A2 receptor**.



Purity: 95.81%
Clinical Data: No Development Reported
Size: 5 mg

Leukotriene B4

(LTB4; 5(S),12(R)-DiHETE)

Cat. No.: HY-107608

Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 25 μg (297.2 μM * 250 μL in Ethanol)

Leukotriene B4-d4

(LTB4-d4; 5(S),12(R)-DiHETE-d4)

Cat. No.: HY-107608S

Leukotriene B4-d4 (LTB4-d4) is the deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 μg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Leukotriene F4

Cat. No.: HY-130440

Leukotriene F4 (LTF4), is a lipid that belongs to the Cysteinyl Leukotriene (CysTL) family. Leukotriene F4 induces bronchoconstriction with an **ED_{50}** of 16 μg/kg. The precursor of LTF4 is Leukotriene E4 (LTE4), which isformed from the action of a glutamyl transferase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LM-1484

Cat. No.: HY-101686

LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for ^{3}H-LTC4 sites.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LTB4-IN-1

Cat. No.: HY-U00299

LTB4-IN-1 (Compound 6) is a **leukotriene synthesis (LTB4)** inhibitor with an **IC_{50}** of 70 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LTD4 antagonist 1

Cat. No.: HY-U00359

LTD_4 antagonist 1 is a potent, orally active antagonist of **leukotriene D_4 (LTD_4)** with a **K_i** of 0.57 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY210073

Cat. No.: HY-U00263

LY210073 is a **Leukotriene B_4 (LTB_4)** receptor antagonist with an **IC_{50}** of 6.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY223982

(CGS23131; SKF107324)

Cat. No.: HY-112737

LY223982 is a potent and specific inhibitor of **leukotriene B4 receptor**, with an **IC_{50}** of 13.2 nM against [^{3}H]LTB4 binding to LTB4 receptor.



Purity: 100.0%
Clinical Data: No Development Reported
Size: 5 mg

LY255283

Cat. No.: HY-15744

LY255283 is a **LTB_4 receptor (BLT2)** antagonist, with an **IC_{50}** of ~100 nM for [^{3}H]LTB_4 binding to guinea pig lung membranes.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Masilukast

(ZD-3523)

Cat. No.: HY-105221

Masilukast is an orally administered **cysteinyl leukotriene D_4 (LTD_4) receptor** antagonist with potential to treat asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-571 sodium

(L-660711 sodium)

Cat. No.: HY-19989A

MK-571 (L-660711) sodium is a selective, orally active **leukotriene D4 receptor** antagonist, with **K_i**s of 0.22 and 2.1 nM in guinea pig and human lung membranes.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

MK-571-d6 sodium

(L-660711-d6 sodium)

Cat. No.: HY-19989AS

MK-571-d6 (L-660711-d6) sodium is the deuterium labeled MK-571 sodium salt. MK-571 sodium is a selective, orally active **leukotriene D4 receptor** antagonist, with **K_i**s of 0.22 and 2.1 nM in guinea pig and human lung membranes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

MK-886

(L 663536) Cat. No.: HY-14166

MK-886 (L 663536) is a potent, cell-permeable and orally active **FLAP** (IC_{50} of 30 nM) and **leukotriene biosynthesis** (IC_{50}s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive **PPARα** antagonist and can induce **apoptosis**.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Montelukast

(MK0476 free base) Cat. No.: HY-13315A

Montelukast is a potent, selective and orally active antagonist of **cysteinyl leukotriene receptor 1 ($CysLT_1$)**. Montelukast can be used for the reseach of asthma and liver injury.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Montelukast sodium

(MK0476) Cat. No.: HY-13315

Montelukast sodium is a potent, selective and orally active antagonist of **cysteinyl leukotriene receptor 1 (Cysltr1)**. Montelukast sodium can be used for the reseach of asthma and liver injury.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Montelukast-d6

(MK0476-d6 free acid) Cat. No.: HY-13315S

Montelukast-d6 (MK0476-d6 free acid) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of **cysteinyl leukotriene receptor 1 (Cysltr1)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Montelukast-d6 sodium

(MK0476-d6) Cat. No.: HY-13315S1

Montelukast-d6 sodium (MK0476-d6) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of **cysteinyl leukotriene receptor 1 (Cysltr1)**. Montelukast sodium can be used for the reseach of asthma and liver injury.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nedocromil

(FPL 59002) Cat. No.: HY-13448

Nedocromil suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (LTC_4), and **prostaglandin D_2** (PGD_2).



Purity: 98.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Nedocromil sodium

(FPL 59002KP; Nedocromil disodium salt) Cat. No.: HY-16344

Nedocromil sodium suppresses the action or formation of multiple mediators, including **histamine**, **leukotriene C_4** (LTC_4), and **prostaglandin D_2** (PGD_2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ONO4057

(ONO-LB457) Cat. No.: HY-U00252

ONO4057 is a **Leukotriene B_4 receptor** antagonist, with an IC_{50} of 0.7±0.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pranlukast

(ONO-1078) Cat. No.: HY-B0290

Pranlukast is a highly potent, selective and competitive antagonist of peptide **leukotriene**s. Pranlukast inhibits [^{3}H]LTE_4, [^{3}H]LTD_4, and [^{3}H]LTC_4 bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Pranlukast hemihydrate

(ONO-1078 hemihydrate) Cat. No.: HY-B0290A

Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide **leukotriene**s. Pranlukast inhibits [^{3}H]LTE_4, [^{3}H]LTD_4, and [^{3}H]LTC_4 bindings to lung membranes with K_is of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Pranlukast-d4

(ONO-1078-d4)

Cat. No.: HY-B0290S1

Pranlukast-d4 is deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pranlukast-d5

Cat. No.: HY-B0290S

Pranlukast-d5 (ONO-1078-d5) is the deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide **leukotriene**s.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Quininib

Cat. No.: HY-119442

Quininib is a **cysteinyl leukotriene 1 and 2 receptor** antagonist with IC_{50}s of 1.2 and 52 μM for $CysLT_1R$ and $CysLT_2R$, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Quinotolast sodium

(FR71021)

Cat. No.: HY-U00027

Quinotolast sodium in the concentration range of 1-100 μg/mL inhibits **histamine**, LTC_4 and PGD_2 release in a concentration-dependent manner.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

REV 5901

Cat. No.: HY-112532

REV 5901 is a competitive and orally active antagonist of **leukotriene receptor**, with a K_i of 0.7 μM. REV 5901 is also a **5-lipoxygenase** inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RG-12525

(NID 525)

Cat. No.: HY-101676

RG-12525 is a a specific, competitive and orally effective antagonist of the **peptidoleukotrienes**, **LTC4**, **LTD4** and **LTE4**, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC_{50}s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a...



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RS-601

Cat. No.: HY-U00072

RS-601 is a novel **leukotriene D4 (LTD4)/thromboxane A2 (TxA2)** dual receptor antagonist, with antiasthmatic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR2640 hydrochloride

Cat. No.: HY-107610

SR2640 (hydrochloride) is a potent and selective competitive **leukotriene D4/leukotriene E4** antagonist. SR2640 can be used for researching the role of leukotrienes in human asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tipelukast

(KCA 757; MN 001)

Cat. No.: HY-14938

Tipelukast (KCA 757) is a sulfidopeptide **leukotriene receptor** antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.



Purity: ≥99.0%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

U-75302

Cat. No.: HY-105484

U-75302 is a potent inhibitor of **leukotriene B4**. U-75302 is a pyridine analogue. U-75302 has the potential for the research of inflammatory diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Veliflapon

(BAY X 1005; DG-031) Cat. No.: HY-14165

Veliflapon (BAY X 1005; DG-031) is an orally active and selective **5-lipoxygenase activating protein (FLAP)** inhibitor. Veliflapon inhibits the synthesis of the **leukotrienes B4** and **C4**.



Purity: 99.16%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Verlukast

(MK-679; L 668019) Cat. No.: HY-76511

Verlukast is a potent, selective, and orally active antagonist of **leukotriene receptor**. Verlukast has the potential for the research of asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Verlukast-d6

(MK-679-d6; L 668019-d6) Cat. No.: HY-76511S

Verlukast-d6 is a deuterium labeled Verlukast. Verlukast is a potent, selective, and orally active antagonist of **leukotriene receptor**. Verlukast has the potential for the research of asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

YM158 free base

(YM-57158) Cat. No.: HY-U00355

YM158 free base is a potent and selective **LTD_4** and **TXA_2 receptor** antagonist with **pA_2** values of about 8.87 and 8.81, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zafirlukast

(ICI 204219) Cat. No.: HY-17492

Zafirlukast (ICI 204219) is a potent orally active **leukotriene D_4 (LTD_4) receptor** antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Zafirlukast-13C,d3

(ICI 204219-13C,d3) Cat. No.: HY-17492S1

Zafirlukast-13C,d3 is the 13C- and deuterium labeled. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zafirlukast-13C,d6

(ICI 204219-13C,d6) Cat. No.: HY-17492S2

Zafirlukast-13C,d6 is the 13C- and deuterium labeled. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zafirlukast-d7

Cat. No.: HY-17492S

Zafirlukast-d7 (ICI 204219-d7) is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active **leukotriene D_4 (LTD_4) receptor** antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

γ-Linolenic acid ethyl ester

(Ethyl γ-linolenate) Cat. No.: HY-108396

γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a **leukotriene B_4 receptor 4 (LTB_4)** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg